peter_farrell

QRxPharma announces several resignations

pharmafile | July 11, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Campbell, PACE, QRxPharma, farrell, quinn 

Australian pharma development firm QRxPharma has confirmed that its chairman Dr Peter Farrell and director Dr Gary Pace have resigned.

Adding to the firm’s woes directors Peter Campbell and Michael Quinn have also tendered their resignations from its board, all seemingly resulting from difficulties with its pain drug Moxduo.

The company now expects Bruce Hancox and Dr Richard Treagus to be appointed as directors as a result following further consultation. 

Advertisement

“It has been an honour serving as QRxPharma chairman and I certainly share the frustration of shareholders with respect to the development of Moxduo and interactions with the FDA,” said Dr Farrell (pictured). 

At the firm’s general meeting Campbell added: “I would like to take this opportunity to thank my fellow board members, senior management and the entire QRxPharma staff and consultants in both Australia and the US for their commitment and efforts over the past seven years. The departing Board members wish the incoming board and shareholders of QRxPharma every success.”

Related Content

Scottish reforms proven to work says SMC

The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its …

Campbell image

Changing our minds about depression

Alastair Campbell, former Labour spin doctor and depression patient, thinks that mental and physical health …

Kofi Annan speaks at the 'global crisis of depression' summit hosted in Lo

Mental and physical health should be treated equally

The need for a new approach to depression that gives it equal importance to physical …

The Gateway to Local Adoption Series

Latest content